DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Apricoxib is an investigational drug.
There have been 5 clinical trials for Apricoxib. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2008.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Pancreatic Neoplasms. The leading clinical trial sponsors are Tragara Pharmaceuticals, Inc., Jonsson Comprehensive Cancer Center, and Martin Edelman, MD.
Recent Clinical Trials for Apricoxib
|Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer||Jonsson Comprehensive Cancer Center||N/A|
|0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer||Tragara Pharmaceuticals, Inc.||Phase 2|
|0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer||Martin Edelman, MD||Phase 2|